ATC code None PubChem CID 67116280 3D model (Jmol) Interactive image | CAS Number 1293281-49-8 Formula C21H22FN7O Molar mass 407.443 g/mol | |
 | ||
Legal status US: Investigational New Drug | ||
MIN-202 (also known as JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD). As of December 2015, it is in phase II clinical trials for both insomnia and MDD.
References
MIN-202 Wikipedia(Text) CC BY-SA